Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma

This study is testing whether adding a drug called selinexor to the standard chemotherapy regimen (R-CHOP) improves outcomes for people with a specific type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) — particularly the germinal center subtype with high-risk features. **You may be eligible if:** - You are between 18 and 75 years old - You have been newly diagnosed with germinal center B-cell DLBCL (a specific subtype confirmed by biopsy) - You have not previously received chemotherapy or radiation for this cancer (short steroid use is okay) - Your cancer is considered high-risk (prognostic score of 3–5) - Your cancer is visible and measurable on CT or PET scan - You are generally functional and able to care for yourself (ECOG 0–2) - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if:** - You have certain rare subtypes of lymphoma (e.g., primary mediastinal, gray zone, or T-cell rich) - Your lymphoma has spread to your brain or spinal cord - You have previously been treated with selinexor or similar drugs - You have an active uncontrolled infection - You have active hepatitis B, C, or HIV not under control - You are pregnant or breastfeeding - You have a life expectancy of less than 6 months Talk to your doctor to see if this trial is right for you.